Zepp Health Corporation (ZEPP) Q4 2025 Earnings Call Transcript

Zepp Health held its Q4 and full-year 2025 earnings conference call on March 15, 2026; the company posted its press release and slides to the IR site. Presenters included CEO Wang Huang, CFO Leon Deng and IR Director Grace Yujia Zhang, with North America management and an analyst (Siddharth Rajeev) on the call. The excerpt contains standard forward-looking statement disclaimers; no financial results or guidance figures were provided in the available text.

Analysis

Zepp sits in the structural sweet spot beneath the premium smartwatch duopoly: its addressable volume in the sub-$200 segment should be less correlated with Apple’s upgrade cycle and more sensitive to share gains in EMs (India, SEA, Europe). That implies a two-stage path to upside — near-term recovery in ASPs and channel fill (3–9 months) and medium-term margin expansion as unit mix shifts to higher-margin services and bundled health subscriptions over 12–24 months.

Second-order supply effects matter: easing shortages for PPG/IMU modules and cost declines in BLE/SoC components can mechanically add ~150–350 bps to gross margins within 6–12 months if Zepp keeps content per device flat; conversely, any re-shoring or tariff moves would flip that benefit quickly. Distribution partnerships and certification wins (insurance, clinical trial contracts, or FDA-type clearances) are binary catalysts that would convert a hardware story into a recurring revenue multiple play.

Tail risks are regulatory (US/China listings and data-privacy scrutiny) and demand cyclicality tied to channel inventory and holiday promo cadence — these can compress multiple and remove visibility over weeks-to-months. The mispriced angle: the market focuses on unit volumes but underweights potential high-margin services/analytics revenue and incremental B2B licensing, which could unlock a 30–50% re-rating if realized over 12–24 months.

Key Decisions for Investors

• Long ZEPP (equity) with protective puts: Buy ZEPP stock sized 3–5% NAV and buy 6–12 month ATM puts to cap downside (~25–30%). R/R: target 40–60% upside over 12 months driven by margin mix shift; max loss limited to put cost plus equity drawdown.
• Long-dated call spread (defined risk LEAPS): Buy ZEPP Jan-2028 ~25% OTM calls and sell nearer-term Jan-2027 calls to finance premium; position size 2–3% NAV. R/R: asymmetric upside (target 80–120%) with limited premium outlay; patience required 12–36 months for services monetization.
• Relative-value pair: Long ZEPP / Short AAPL (small size, 1% NAV each) over 6–12 months to isolate share gains in the <$200 segment. Rationale: hedge broad market/OS risk while capturing sub-premium share reallocation; unwind if Apple launches an aggressive lower-price SKU or Zepp misses distribution milestones.
• Short-term option income trade ahead of next quarter: Sell a 1–2 month put spread (cash-secured) for a modest credit if you expect muted earnings downside and stable channel inventories. Risk_defined: limited to spread width; return: 5–10% of notional if trade expires worthless within 30–60 days.